NovaBay Pharmaceuticals, Inc. (NBY) is seeing its stock rise after announcing the sale of its Avenova assets to Physician Recommended Nutraceuticals (PRN) for $9.5 million. The deal is expected to close in the fourth quarter of 2024, pending shareholder approval.